Alexander Pasteur
Partner @ F-Prime
London, United Kingdom
Alexander Pasteur is a Series B investor at F-Prime in London focused on Biotechnology and Health Care. Alexander Pasteur is based out of London, England and is the Partner of F-Prime. Alexander previously worked at MVM Life Science Partners as a Partner. Alexander Pasteur attended the University of Cambridge.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Alexander Pasteur invests in
Stages Alexander Pasteur invests in
Countries Alexander Pasteur invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (46%)
- Health Care 4 (31%)
- Pharmaceutical 4 (31%)
- Medical 2 (15%)
- Clinical Trials 2 (15%)
Stage
- Series B 6 (46%)
- Series A 5 (38%)
- Seed 1 (8%)
Country
- United Kingdom 4 (31%)
- United States 2 (15%)
- The Netherlands 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | $85M / Series B / Jan 28, 2026 | ||
| ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M / Series B / Jul 29, 2025 | ||
| ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $90M / Series A / Dec 07, 2023 | ||
| Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | $70M / Series A / Jul 12, 2023 | ||
| ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $23M / Seed / Jun 21, 2023 | ||
| Castor is an international health-tech company founded by CEO Derk Arts, MD, Ph.D. Their cloud-based clinical data platform simplifies the entire clinical trial process, from recruitment to analysis, for researchers worldwide. More than 50,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform hassupported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 180,000,000 data points and 2,000,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse. | $45M / Series B / Jul 14, 2021 | ||
| NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $55M / Series B / Jun 03, 2020 | ||
| Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer.They use AI to identify new drug candidates, de-risk and accelerate clinical trials and builddiagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi. | $25M / Series A / May 07, 2020 | ||
| Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer.They use AI to identify new drug candidates, de-risk and accelerate clinical trials and builddiagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi. | $13M / Series A / Mar 07, 2019 | ||
| NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $40M / Series A / Jun 25, 2018 | ||
| See all 13 investments → | |||
Co-Investors
About F-Prime
F-Prime enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. Our legacy spans over 50 years, built on the belief that the best investors share the same entrepreneurial spirit of the founders they back—and that conviction still guides us today.Inhealthcare, we focus on therapeutics, medtech, and healthtech + services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech, and crypto. While we’re early-stage investors by choice, we’ll back exceptional teams at any stage.Today, our $4.8 billion under management support breakthroughs across healthcare and technology. Our seasoned team of scientists, engineers, physicians, operators, and investors bring real world expertise to help companies accelerate their path to scalable growth, always with an eye towards a shared vision—achieving something incredible.
F-Prime Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexander Pasteur
Partner
|
|||
Sanjay Aggarwal
Venture Partner
|
|||
Shervin Ghaemmaghami
Operating Partner
|
|||
Stacie Weninger
Executive Director
|
|||
Ben Gorman
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexander Pasteur invest in?
Alexander Pasteur invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexander Pasteur?
Public channels for Alexander Pasteur include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexander Pasteur last invest?
The most recent investment recorded for Alexander Pasteur closed in Jan 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
